Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 24, 2026

As Tim Cook Steps Aside, What's Next for Apple?

View original at nasdaq.com
As Tim Cook Steps Aside, What's Next for Apple?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • T-Mobile trades at 2.5 times sales

    60% confidence
  • Service revenue was about 5% of Apple's business when Cook took over, now more than 25%

    60% confidence
  • AST SpaceMobile satellite that went into wrong orbit will be deorbited

    60% confidence
  • Stock Advisor's total average return is 967% vs 199% for S&P 500

    60% confidence
  • If you invested $1,000 in Netflix on December 17, 2004 based on Stock Advisor recommendation, you'd have $500,572

    60% confidence
  • Bringing in a hardware engineer as CEO doesn't guarantee a new breakthrough product

    60% confidence
  • There is about $2.8 trillion in passive S&P 500 index ETFs

    60% confidence
  • Apple now has more than 1 billion paid subscriptions throughout its ecosystem

    60% confidence
  • Apple's profits are up about 700% since Tim Cook took over as CEO

    60% confidence
  • Apple is not among the 10 best stocks for investors to buy now according to Stock Advisor

    60% confidence
  • AST SpaceMobile investment is speculative at best with a lot of execution risk

    60% confidence
  • AST SpaceMobile has $31 billion market cap for essentially a pre-revenue company with $1.2 billion revenue commitments

    60% confidence
  • AST SpaceMobile has just over $3 billion in cash to build out their satellite constellation

    60% confidence
  • AST SpaceMobile needs to complete 45 to 60 launches this year to start generating revenue

    60% confidence
  • There are not enough reliable launch partners right now in the space industry

    60% confidence
  • Firefly Aerospace is beginning to look like a reliable launch partner

    60% confidence
  • If SpaceX were added to S&P 500 at $2 trillion valuation, it would account for almost 3% of the index's weight

    60% confidence
  • AST SpaceMobile is traded at a conservative 130 times future sales

    60% confidence
  • Getting the AI strategy right could be just as big as a new product launch for Apple

    60% confidence
  • Companies that establish themselves as reliable launch providers will succeed

    60% confidence
  • Index fund players would need to amass at least 20% stake in SpaceX if included in S&P 500

    60% confidence
  • Rocket Lab is the best space investment idea right now

    60% confidence
  • Apple was right not to build its own car

    60% confidence
  • If you invested $1,000 in Nvidia on April 15, 2005 based on Stock Advisor recommendation, you'd have $1,223,900

    60% confidence
  • 30% of all assets under management in top 100 ETFs are allocated to S&P 500

    60% confidence
  • Not having SpaceX in the S&P 500 makes the index less reflective of the overall market

    60% confidence
  • Apple shares generated about 3,100% total returns under Tim Cook compared to 731% for S&P 500

    60% confidence
  • Tim Cook's lasting legacy is stability - he kept the plane on course

    60% confidence
  • Being behind the curve on AI innovation is one of the biggest challenges for Apple's new leadership

    60% confidence
  • Having the customer is more valuable than having the AI model in two years

    60% confidence

Data points we hold from this source

S&P 500 · total average return199 percent
SpaceX · valuation2 trillion_USD
SpaceX · sp500 weight3 percent
SpaceX · ipo raise amount90 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com